Clinical trials: MGUS
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Signification
Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy
Blood circulating endothelial cells (CEC) and microparticles (MPs) are described in the literature to be associated with vascular failures and dysfunction that reflect neo-angiogenesis and risk of thrombosis, respectively.
- Conditions
- Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Signification, Myeloma
- Trial name
- PACMoG (NCT01543100)
- Testing
- blood and bone marrow samples
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Rennes University Hospital
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00899353
- Testing
- Omega 3 Fatty Acid
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Marshall University
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, is feasible for patients with myeloma precursor disease or newly…
- Conditions
- Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
- Trial name
- FAST-M (NCT07446777)
- Testing
- Health Coaching, Prolonged Overnight Fasting (POF), Mediterranean Diet
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Miami
Multiple Myeloma, Leukemia
Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
Background: Multiple myeloma (MM), a type of cancer that affects the white blood cells, is often preceded by a precancerous disorder known as monoclonal gammopathy of undetermined significance (MGUS).
- Conditions
- Multiple Myeloma, Leukemia, MGUS, Monoclonal B-Cell Lymphocytosis
- Trial name
- NCT01139476
- Where
- United States
- Volunteers
- 1,892 people
- Sponsor
- National Cancer Institute (NCI)
Influenza, Multiple Myeloma
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
The investigators' hypothesis is that the administration of Fluzone® High-Dose with booster to all patients with monoclonal gammopathies (irrespective of age) will lead to seroconversion rates exceeding 50% and more importantly…
- Conditions
- Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders
- Trial name
- SHIVERING 2 (NCT02566265)
- Testing
- Fluzone High Dose Vaccine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Yale University
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Beta Alethine in Treating Patients With Myeloma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006466
- Testing
- beta alethine
- Where
- 3 sites in United States
- Sponsor
- LifeTime Pharmaceuticals
Pruritus, Monoclonal Gammopathy
Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy
Pruritus is most often secondary to dermatitis but can also occur without skin lesions, it is called pruritus sine materia. The causes of pruritus sine materia are various: haematological (myeloproliferative neoplasia ...)…
- Trial name
- PRURIGAMMA (NCT03832140)
- Where
- France
- Volunteers
- 281 people
- Sponsor
- University Hospital, Brest
Monoclonal Gammopathy, Tuberculosis
Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis
The purpose of this study is to determine whether the monoclonal protein in patients with tuberculosis and monoclonal gammopathy has anti-tuberculous activity, and whether genes coding their monoclonal proteins show…
- Trial name
- NCT00173264
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma.
- Trial name
- NCT05136807
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Monoclonal Gammopathy of Undetermined Significance
Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery
Screening study to determine incidence of MGUS in this patient population
- Trial name
- NCT03855878
- Where
- United States
- Volunteers
- 209 people
- Sponsor
- Indiana University
Multiple Myeloma
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
This study is designed to decrease toxicity associated with prior tandem transplant protocols by reducing the intensity of induction, consolidation and maintenance therapy, while increasing event-free survival by adding…
- Trial name
- NCT01548573
- Testing
- Dexamethasone, Tandem autologous stem cell transplant, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Iowa
AL Amyloidosis, MGUS
Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
Immunoglobulin light chain (AL) amyloidosis is caused by a typically small, minimally proliferating bone marrow plasma cell clone secreting a patient-unique, unstable, aggregation-prone, toxic light chain (LC).
- Conditions
- AL Amyloidosis, MGUS, Multiple Myeloma, Monoclonal Gammopathies
- Trial name
- GlycAL (NCT07448779)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Anemia, Leukemia
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00416624
- Testing
- darbepoetin alfa, epoetin alfa, fatigue assessment and management
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- Mayo Clinic
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)…
- Trial name
- NCT04850846
- Testing
- Metformin XR
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Monoclonal Gammopathy of Undetermined Significance (MGUS), Non-IgM Monoclonal Gammopathy of Undetermined Significance
A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells
This study evaluates a novel laboratory method to study how certain bone marrow cells in the body take up nutrients from their environment.
- Trial name
- NCT07057583
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Multiple Myeloma, Neoplasms
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different belantamab mafodotin doses in combination with daratumumab, lenalidomide and dexamethasone.
- Conditions
- Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal
- Trial name
- NCT05280275
- Testing
- Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide
- Where
- 2 sites in Greece
- Volunteers
- 36 people
- Sponsor
- Hellenic Society of Hematology